Biotechnology
Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS
NANTONG and SUZHOU, China, Dec. 24, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I clinical trial of RAG-17, an innovative siRNA t...
2024-12-24 20:00
790
Inauguration of MRI Facility and Health Service Initiative at Bhayangkara Kediri Hospital, Featuring DNA Testing Services in Collaboration with Regene Genomics
JAKARTA and KEDIRI, Indonesia, Dec. 24, 2024 /PRNewswire/ -- Bhayangkara Kediri
Hospital inaugurated its new MRI service building and laid the cornerstone for
a new service facility, marking a significant step forward in enhancing
healthcare services in Kediri and surrounding areas.
2024-12-24 12:38
1197
Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis
CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") ofChina has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade nam...
2024-12-23 22:31
1400
Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership to Build a New Ecosystem for ADC Drug Development, Production, and Supply Chain
CHONGQING, China, Dec. 23, 2024 /PRNewswire/ -- On December 20, 2024, Porton Pharma Solutions (hereinafter referred to as "company" or "Porton") and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as "Dragon Sail Pharmaceutical") formally si...
2024-12-23 21:00
1518
SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore
* SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process development and clinical translation. * The parti...
2024-12-23 09:00
1322
Macrogen Consortium win tender for National Bio Big Data Project
Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium. SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and arra...
2024-12-23 08:00
1582
United Imaging Intelligence at RSNA 2024: Empowering a More Intelligent and Connected World with Medical AI
CHICAGO, Dec. 20, 2024 /PRNewswire/ -- As RSNA 2024 concluded, United Imaging Intelligence (UII), a subsidiary of United Imaging Group specializing in medical AI, made a significant impression with a visionary showcase that seamlessly aligned with the event's theme: "Building Intelligent Connecti...
2024-12-20 22:00
1177
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr.Lilly Xu as its new Chief Technology Officer (CTO). With over30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation and ...
2024-12-20 21:30
1068
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma
* Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive$6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation. * Patients with relapsed/refractory follicular lympho...
2024-12-19 23:00
1565
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
* Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY * Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY * Gross margin increased to 82.6% from 80.9% in the same period of FY2024 * Total operating expenses decreased to RMB 276.4 million, down 31.6%...
2024-12-19 22:05
2072
Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements
Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen
and Overall Wellness
IM8, a New Premium Supplements Brand, Launched Officially on November 18th on
IM8health.com
2024-12-19 21:30
1880
MGI Tech Closes Agreement with Sabin Group to Boost Personalized Medicine in Brazil through Oncological and Germiline Genomics
Partnership helps expand population access to cutting-edge genomic tests SAO PAULO, Dec. 19, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has recently partnered with Sabin Group, one of the lar...
2024-12-19 17:42
947
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South,Belgium, facilita...
2024-12-19 17:02
1712
LG Corp. Chairman and CEO Kwang Mo Koo sends 2025 New Year Address to 270,000 global employees on December 19
* "Let's Shape LG's Future with the DNA of Challenge and Change We've had Since Day 1" * Highlighting LG's Spirit – the DNA of challenge and change since Day 1 - "LG's Day 1 spirit of choosing what others wouldn't dare comes from our DNA of challenge and change as we serve our customer...
2024-12-19 13:00
1193
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS")China on December 16th. The partnership was officially formalized with the signing of a colla...
2024-12-19 12:40
1011
Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection
LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight, a liquid bi...
2024-12-19 01:00
1815
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer. * The product, termed SAR-bisFAP, has shown strong tumour targeting...
2024-12-18 22:03
1346
Juncell Therapeutics Opens State-of-the-Art Facility for TIL Production
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, announced the grand opening of its state-of-the-art TIL manufacturing facility loc...
2024-12-18 21:08
1211
Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery
- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic develop...
2024-12-18 13:09
1641
U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
* STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) * STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio a...
2024-12-18 11:50
870
Week's Top Stories
Most Reposted
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
[Picked up by 323 media titles]
2024-12-19 13:41
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 309 media titles]
2024-12-20 16:25
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
[Picked up by 306 media titles]
2024-12-19 17:56
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 304 media titles]
2024-12-20 18:11
MediSun Energy Joins the Abu Dhabi Sustainable Finance Declaration, Reinforcing Commitment to Sustainable Solutions in the UAE
[Picked up by 290 media titles]
2024-12-18 15:35
Most Read
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
7880
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
2024-12-19 17:56
7593
